Adjuvant formulations comprising TLR4 agonists and methods of using the same
US11510875B2 · kind B2 · utility
0Cited by
134References
61Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 7, 2013 |
| Grant date | Nov 29, 2022 |
| Priority date | — |
| Expiry date | Feb 7, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/16234
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Formulations and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed. The formulations generally comprise a TLR4 agonist and a metabolizable oil at a concentration of about 0.01%-1% v/v, wherein the hydrophobic:lipophilic balance (HLB) of the emulsion is greater than about 9.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.